



I hereby certify that this paper is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop AF; Commissioner for Patents, Box 1450, Alexandria, VA 22313-1450 on Account 1823, 2003.

alande se bords

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicants:

Michael Sundström et al

Paper No:

Serial No.:

09/355,664

Group Art Unit:

1646

Filed:

October 8, 1999

Examiner:

O. Chernyshev

For:

Modified Cytokine Receptor Protein

REQUEST FOR RECONSIDERATION UNDER 37 C.F.R. 1.116 RECEIVED

Mail Stop AF Commissioner for Patents Box 1450 Alexandria, VA 22313-1450

TECH CENTER 1600/2900

AUG 2 5 2003

Dear Sir:

In response to the Official Action dated May 22, 2003, Applicants request reconsideration of the patentability of claims 1, 2, 5-8 and 42-43 in view of the following remarks. Applicants acknowledge and appreciate the allowance of claims 9 and 10.

REMARKS

The Official Action dated May 22, 2003 has been carefully considered. Accordingly, it is believed that the following remarks are sufficient to demonstrate the patentability of claims 1, 2, 5-8 and 42-43, and place the present application in condition for allowance.

Reconsideration is respectfully requested.

Claims 1, 2, 5-8 and 42-43 were rejected under 35 U.S.C. 112, first paragraph as not being enabled by the instant specification. Specifically, the Examiner asserts that the instant specification is enabling for a modified human growth hormone receptor (hGHR) consisting